Description
Pharmacological Targets in Metabolic Diseases: Challenges and Opportunities is a complete reference on possible drug development targets to be leveraged in therapeutic developments. Covering both signaling pathways and specific proteins, the book presents ways to modulate the molecular and cellular alterations observed in metabolic diseases and disorders through the application of new or classical drugs. The comprehensive coverage starts by providing an overview of metabolic diseases and disorders, biological alterations, and pharmacological targets. This section covers targets at both molecular, and subcellular and cellular levels. The next section in the book is focused on pharmaceutical targeting of organs, including a dedicated chapter to the gut-brain axis. Next comes a thorough review of the current advances in metabolic syndrome research. Section VI is focused on inborn errors of metabolism and is followed by a section devoted to natural molecules and their pharmacological potential to treat these conditions. The Editor introduces next a whole section dedicated to the role of the microbiota in metabolic diseases therapeutics. The following sections cover the impact of aging, nanotechnology, the environment, and finally diagnostic techniques in metabolic diseases and disorders. Pharmacological Targets in Metabolic Diseases: Challenges and Opportunities meet the needs of pharmacology researchers looking for a comprehensive and authoritative source of information on possible therapeutic targets to treat these conditions. Research physicians, nutritionists, pharmacists, and biologists can benefit from the detailed information provided at the different levels of targets identified to treat metabolic diseases and conditions.- Covers the most prevalent metabolic diseases and disorders such as metabolic syndrome, diabetes mellitus (types I and II) and dyslipidemia, among others- Includes chapters on the microbiome and environmental pollution as they relate to metabolic diseases and conditions- Discusses cellular structures like the endoplasmic reticulum and mitochondria as pharmacological targets
Table of Contents
Part I: Subsection: Overview of metabolic diseases and disorders, biological alterations, and pharmacological targetsSection I: Molecular level1. Molecular and cellular targets in the management of metabolic diseases and disorders: an overview2. Pharmaceutical aspects of conventional and recent developments for the treatment of metabolic diseases and disorders3. NADPH oxidase, obesity and metabolic syndrome: therapeutic opportunity4. Targeting reactive carbonyls in metabolic disordersSection II: Subcellular and cellular levels5. Targeting autophagy in metabolic diseases6. Endoplasmic reticulum as a pharmacological target in metabolic diseases7. Pharmacologically targeting caveolae in metabolic diseasesPart II: Subsection: Organs as pharmacological targets in metabolic diseases and disorders8. The gut-brain axis as a pharmacological target for depressive disorder and Alzheimer's disease in diabetes {i|mellitus}9. Cardiomyopathy in metabolic diseases: pharmacological strategies10. Diabetic kidney disease: treatment and challenges11. Unraveling the Enigma of Non-Alcoholic Fatty Liver Disease: From Pathogenesis to Therapeutic Horizons12. Pharmacologic intervention of nonalcoholic steatohepatitis and related cirrhosisPart III: Subsection: Obesity13. Pharmacological targets in obesity14. Adipose tissue and metabolic diseases: a target for prevention and treatment of metabolic diseasesPart IV: Subsection: Metabolic syndrome15. Metabolic syndrome: pharmacological strategies and challenges16. Pharmacological targets in metabolic syndrome-related dyslipidemia17. Plant molecules and metabolic syndrome: therapeutic opportunitiesPart V: Subsection: Natural molecules and metabolic diseases and disorders18. Polyphenols and obesity: molecular targets and therapeutic potential19. Plant Molecules: Prevention and Management of Diabetes Mellitus20. Molecular targets in dyslipidemia: therapeutic potential of plant molecules21. Polyphenols and the control of immunometabolism as a pharmacological targetPart VI: Subsection: Microbiota and metabolic diseases and disorders22. Microbiota, metabolic disorders and pharmacological opportunities23. Gut microbiota as a pharmacological target in cardiovascular diseases24. Plant molecules in obesity and the gut microbiota25. Microbiota and fatty liver disease: potential candidate for therapeutic interventionPart VII: Subsection: Nutrition and food interactions26. Nutrition and Drug Interactions in Metabolic Diseases
